Publications by authors named "S Zanetta"
Lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib in treatment of advanced renal cell carcinoma (aRCC) in the phase 3 CLEAR study. We report results of an exploratory post hoc analysis of tumor response data based on baseline metastatic characteristics of patients who received lenvatinib plus pembrolizumab versus sunitinib, at the final overall survival analysis time point of CLEAR (cutoff: July 31, 2022). Treatment-naïve adults with aRCC were randomized to: lenvatinib (20 mg PO QD in 21-day cycles) plus pembrolizumab (n = 355; 200 mg IV Q3W); lenvatinib plus everolimus (not reported here); or sunitinib (n = 357; 50 mg PO QD; 4 weeks on/2 weeks off).
View Article and Find Full Text PDFPurpose: Treatment options for advanced head and neck squamous cell carcinoma (HNSCC) previously treated with platinum-based chemotherapy and a programmed death-1 (PD-1) inhibitor are limited. Trophoblast cell-surface antigen 2 (Trop-2) is highly expressed in HNSCC. Sacituzumab govitecan (SG) is a Trop-2-directed antibody-drug conjugate approved for patients with certain previously treated solid tumors.
View Article and Find Full Text PDFTrifluridine/tipiracil-bevacizumab is a standard of care in metastatic colorectal cancer (mCRC) after chemotherapy failure. We aim to assess the addition of XB2001 (anti-IL-1 alpha monoclonal antibody) plus trifluridine/tipiracil-bevacizumab in mCRC refractory to standard chemotherapy. This multicenter, randomized, double blind, non-comparative Phase I-II study (ClinicalTrials.
View Article and Find Full Text PDFArticle Synopsis
- Nintedanib is a drug being tested for effectiveness against advanced thyroid cancers, specifically radioiodine refractory differentiated thyroid cancer (RAIR DTC) and medullary thyroid cancer (MTC), in a phase II clinical trial (EORTC-1209).
- The study compared nintedanib with a placebo for its effects on progression-free survival (PFS) among patients, showing a median PFS of 3.7 months for nintedanib vs. 2.9 months for placebo in the RAIR DTC cohort, although no objective responses were noted in either group.
- Adverse effects were more common in the nintedanib group, with about
Article Synopsis
- This study investigates the effectiveness of two surfactant administration methods—INtubate-RECruit-SURfactant-Extubate (IN-REC-SUR-E) and less invasive surfactant administration (LISA)—on improving BPD-free survival in preterm infants with respiratory distress syndrome (RDS).
- A total of 382 preterm infants, born at 24-27 weeks' gestation and not intubated at birth, will be randomly assigned to either method within the first 24 hours of life. The primary outcome being measured is a combination of death or bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual age.